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Background: Staurosporine inhibits most protein kinases at low nanomolar
concentrations. As most tyrosine kinases, along with many serine/threonine
kinases, are either proto oncoproteins or are involved in oncogenic signaling,
the development of protein kinase inhibitors is a primary goal of cancer
research. Staurosporine and many of its derivatives have significant biological
effects, and are being tested as anticancer drugs. To understand in atomic
detail the mode of inhibition and the parameters of high-affinity binding of
staurosporine to protein kinases, the molecule was cocrystallized with the
catalytic subunit of cAMP-dependent protein kinase.
Results:  The crystal structure of the protein kinase catalytic subunit with
staurosporine bound to the adenosine pocket shows considerable induced-fit
rearrangement of the enzyme and a unique open conformation. The inhibitor
mimics several aspects of adenosine binding, including both polar and nonpolar
interactions with enzyme residues, and induces conformational changes of
neighboring enzyme residues.
Conclusions:  The results explain the high inhibitory potency of staurosporine,
and also illustrate the flexibility of the protein kinase active site. The structure,
therefore, is not only useful for the design of improved anticancer therapeutics
and signaling drugs, but also provides a deeper understanding of the
conformational flexibility of the protein kinase.
Introduction
Highlighting the key role protein kinases play in cellular
signaling, defects in kinase regulation are often associated
with cancer and other diseases. Among exogenous inhibitors
of protein kinases, the microbial alkaloid staurosporine
from Streptomyces sp. [1,2] is the most potent general
inhibitor known so far. It binds with extraordinarily high
affinity (1–20 nM) to most members of the serine/threo-
nine subfamily of protein kinases, including cyclin-
dependent kinase p34cdc2 (p34cdc2) [3], protein kinase C
(PKC) [4], Ca2+-dependent protein kinase (CaMK) [5],
and also protein tyrosine kinases, such as v-Src kinase
[6], platelet-derived growth factor (PDGF) receptor
kinase [7] and insulin receptor kinase (IRK) [8], among
many others. Staurosporine has diverse effects on cells,
including the induction of cell differentiation [9,10] and
the induction of apoptosis [11–13]. This compound has
significant cytotoxic and antiproliferative effects in vitro and
several staurosporine analogs show antitumor activity in
animal models [14,15] and are candidates for clinical trials
(e.g. NCI-95-C-0171C and NCI-T95-0052N P). The
inhibitory mechanism of staurosporine is ambiguous, as
both competitive and noncompetitive kinetics versus
MgATP have been reported [16–18]. The kinetics of
staurosporine binding versus substrate is classified as
noncompetitive in tyrosine kinases. In serine/threonine
kinases, however, staurosporine binding is uncompetitive
versus substrate [17]. To clarify the mode of staurosporine
binding and to determine parameters leading to protein
kinase specificity, we have used the catalytic subunit Ca
of cAMP-dependent protein kinase (cAPK), which is
inhibited by staurosporine with a Ki of 8 nM, as a struc-
tural model system.
Several recently determined crystal structures have
shown different protein kinases to have highly similar
structures, thus, individual characteristics arise from
rather subtle structural differences. Most of the invariant
residues of protein kinases line the active site in the
binding region of the triphosphoryl group. The adeno-
sine-binding pocket is much less conserved, providing a
basis for the selectivity of ATP-competitive protein kinase
inhibitors [19–25]. Due to the high interest in the kinase
inhibitor staurosporine, several laboratories have modeled
its binding to the cAPK catalytic subunit [25,26]. The
crystal structure of this complex, however, reveals a
number of surprising conformational effects of complex
formation. Staurosporine binds to the adenosine-binding
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site and binding is accompanied by induced fit confor-
mational changes at residues which line the binding site.
Furthermore, the catalytic subunit adopts an open con-
formation which differs from previously observed confor-
mations. The knowledge of the detailed binding inter-
actions of staurosporine should aid the development of
selective protein kinase inhibitors.
Results and discussion
The bovine recombinant catalytic subunit of cAPK (rCa)
[27] in a ternary complex with the pseudo-substrate
protein kinase inhibitor peptide (PKI(5–24)) and stauro-
sporine (St) (St–rCa –PKI) crystallized in the ortho-
rhombic space group P212121 (Table 1). The unit cell
dimensions are the smallest observed so far for crystals of
the rC subunit. The unit cell of P212121 crystals of the
bovine rC subunit complexed with isoquinolinesulfonyl
inhibitors varied (within 0.2 Å) around a = 73.5, b = 76.2,
c = 80.5 Å [19], values which are also typical for the mouse
recombinant rC subunit crystallized under different condi-
tions [28,29]. The new unit cell dimensions in the pres-
ence of staurosporine probably result from a more compact
packing of the asymmetric units. This seems likely to be a
consequence of staurosporine binding, although other
spurious effects, such as those arising from the freezing of
the crystals for data collection, cannot be ruled out.
However, indexing at room temperature prior to freezing
indicated similar cell dimensions. Phosphoryl groups are
visible on residues Thr197 and Ser338.
Several crystal structures of the mouse (mC) or bovine
recombinant and the native porcine cAPK C subunit have
been described in a number of forms: in binary complexes
with PKI(5–24) [28], in ternary complexes with additional
nucleotides [29–31] or isoquinolinesulfonamide inhibitors
[19], in the unbound apoform [32], and in a binary
complex with adenosine [33]. Catalysis requires a closed
conformation of the enzyme, represented by the struc-
tures of the ternary complexes with Mg2+ATP [30] or
Mn2+AMP-PNP [31], and PKI(5–24). In these structures
the nucleotide binds with the triphosphoryl group close to
the opening of a cleft which separates the smaller N-ter-
minal (upper; N) lobe from the larger C-terminal (lower;
C) lobe of the protein. The g -phosphate faces the peptide
(pseudo-)substrate site, and the adenosine moiety is well
buried inside the cleft. An ‘open’ conformation, where the
N lobe is rotated away from the C lobe, was observed for
the enzyme as cocrystallized with a diiodinated peptide
[34], and for the free apoform. All ternary complexes so far
reported are in a closed conformation.
In the structure of the St–rCa –PKI complex (Figure 1), the
greater part of the N lobe is rotated away from the C lobe
by 10° relative to the closed conformation of AMP-PNP–
mC–PKI (Figure 2). In the previously reported open con-
formation of mC in complex with diiodinated PKI(5–24)
(mC–PKI; PDB entry code 1CMK [34]), the N lobe is
rotated by 11° [33]. Although the St–rCa –PKI structure can
be described as an open conformation, its N lobe has a con-
formation more closely related to that of the N lobe of the
AMP-PNP–mC–PKI complex, with a root mean square
deviation (rmsd) of 0.73 Å for the backbone atoms of
residues 32–125. This is in contrast to a corresponding rmsd
of 0.95 Å for St–rCa –PKI and mC–PKI, or 1.04 Å for AMP-
PNP–mC–PKI and mC–PKI. The conformation of St–rCa –
PKI is unlike other open conformations in several respects;
these differences concern the central regions of the first
three b strands, the C-terminal nonconserved tail of the
kinase, the catalytic loop including the catalytic base
Asp166, and the metal-binding loop around Thr183.
The binding mode of staurosporine
The electron density of the staurosporine molecule occu-
pies the adenosine-binding site in the cleft between the
two lobes of the enzyme that contains the active site
(Figure 3), mimicking several aspects of adenosine binding.
The binding site of staurosporine was previously unclear,
because of conflicting data from inhibition kinetics.
Competitive [5] as well as noncompetitive [4,8,16] kinet-
ics versus MgATP have been observed. Herbert et al. [5]
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Table 1
Data collection and refinement statistics for St–rCa–PKI.
Data collection
Space group P212121
Cell (a, b, c) (Å) 68.99, 72.82, 76.63
Resolution range (Å) 32–2.3
Observed reflections 64 256
Unique reflections 16 993
Completeness (%) 92.2
Completeness in the last shell (2.38–2.3) (%) 92.3
I / sigma I in the last shell (2.38–2.3) 3.0
Rmerge* (%) 7.3
Rmerge* in the last shell (2.38–2.3) (%) 24.6
Refinement
Number of active protein atoms 2911
Number of inhibitor atoms 35
Number of water atoms 142
R factor (%) 20.8
Free R factor (%) 33.3
Resolution range (Å) 8.0–2.3
Used reflections ( >2 s ) 15 467
Standard deviation from ideal values
Bond length (Å) 0.012
Bond angles (°) 1.547
Standard deviation in B factors 
for bonded atoms (Å2) 3.244
Temperature factors
All atoms 34.641
Mainchain atoms 33.648
Sidechain atoms 34.102
Inhibitor atoms 37.516
Solvent molecules 48.905
*Rmerge = S | Iobs – < I > | S Iobs.
reported competitive inhibition towards MgATP, but
a failure of the isoquinolinesulfonamide H-7 and H-8
inhibitors to compete with 3H-staurosporine binding to the
cAPK C subunit, suggesting different binding sites for stau-
rosporine and isoquinolinesulfonamide inhibitors. Meggio et
al. [17] reported a kinetic mechanism for staurosporine
which is competitive versus MgATP in serine/threonine
and tyrosine kinases, and which is uncompetitive versus
substrate in serine/threonine kinases, but noncompetitive
versus substrate in tyrosine kinases. Crystal structures
clearly show that staurosporine, the isoquinolinesulfon-
amide inhibitors H-7, H-8, H-89 [19], and the adenosine
moiety [31] occupy the same binding site, at least in the
catalytic subunit of cAPK.
The binding mode of staurosporine to the enzyme can best
be described in comparison to the binding of ATP. The
structures of St–rC–PKI and AMP-PNP–mC–PKI were
aligned using backbone atoms of the two central helices E
and F from the C lobes (residues 140–159 and 219–232),
which show an rms deviation of 0.256 Å  (Figure 2). In this
superposition, the indole carbazole rings of staurosporine
and the purine rings of the nucleotide lie almost in the
same plane (Figure 4), with a 12° tilt of staurosporine,
lifting the indole carbazole ring III towards the N lobe.
The purine five-membered ring roughly superimposes
with the central indole carbazole six-membered ring II.
Both sugar moieties intersect at their ring oxygens, but the
tetrahydropyran ring, in the boat conformation, has an ori-
entation rotated about an axis along the plane, bringing the
methylamino nitrogen of staurosporine close to the 3¢ OH
of ATP. The C35 methyl group of staurosporine approxi-
mately replaces the 5¢ C atom of ATP. The massive indole
carbazole rings I and III extend much farther than the
adenosine moiety, while the position of the triphosphate
group is left unoccupied. The coincident positions of the
ribose ring oxygen, the oxygens of the sulfonyl group of
the isoquinolinesulfonamide inhibitors and the ring oxygen
O29 of the staurosporine tetrahydropyran ring imply a role
of an oxygen atom in this position that is important for
protein kinase specificity. None of these oxygen atoms,
however, form apparent direct electrostatic or hydrogen-
bond interactions with the enzyme.
The purine base of ATP is anchored to the C subunit by
three hydrogen bonds, two of which appear to be con-
served among kinases [31]. One bond exists between the
N1 of ATP and the backbone amide of Val123, the second
is between N6 and the backbone carbonyl of Glu121.
Both these interactions are mimicked by staurosporine
(Figure 5). The N19 amide of the staurosporine lactam
ring interacts with the Glu121 carbonyl, and the lactam
carbonyl O30 interacts with the Val123 amide. A noncon-
served third interaction of the Thr183 hydroxyl group to
N7 of ATP is not possible with the hydrophobic rings of
staurosporine. This interaction, however, appears not to
be a major determinant of ATP binding, as several
kinases have residues which cannot form hydrogen bonds
in this position [35]. The ribose of ATP interacts with two
residues of the enzyme: via its 2¢ OH group to the
sidechain of Glu127 and via its 3¢ OH group to the main-
chain carbonyl of Glu170. Similar interactions are pro-
vided by the methamino N31 of staurosporine (Figure 5).
Another interaction of the 3¢ OH of ATP to the sidechain
of the peptide P-3 arginine, part of the substrate recog-
nition sequence of PKI(5–24), is not established in the
St–rCa –PKI structure. In the St–rCa –PKI structure, this
arginine residue has a different rotamer conformation,
which was observed previously in the isoquinolinesulfon-
amide–inhibitor complexes, and (with partial occupancy)
in a binary complex with PKI(5–24) [36]. Apparently, the
additional interaction of this residue with Thr51, which
results due to a closure of the glycine-flap induced by
the triphosphate of ATP, is a more attractive interaction
than that formed by the secondary amine of an inhibitor
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Figure 1
Complex of the bovine cAPK catalytic subunit with the protein kinase
inhibitor staurosporine and PKI(5–24). Helices are shown in turquoise,
except for the N-terminal helix of PKI(5–24) which is shown as a purple
cylinder. b Sheets are shown as large pink arrows and turns as small
blue arrows. The loop containing the pseudo-substrate region of
PKI(5–24) is shown in purple. Staurosporine is shown in ball-and-stick
representation in atom colors, red for oxygen, blue for nitrogen and
yellow for carbon.
molecule alone. The methoxy group of staurosporine
makes no direct contact. Most of the polar interactions of
the ATP molecule are formed via the triphosphoryl group
to invariant conserved residues, and thus do not have
equivalents in staurosporine.
The staurosporine-binding pocket
After induced conformational changes, the enzyme is
nearly perfectly complementary to the large staurosporine
molecule which fills the cleft between the two lobes in the
adenosine subsite (Figures 6a,b). This binding pocket for
staurosporine is defined by many of the residues which
also contribute to adenosine binding, namely Leu49,
Gly50, Val57, Ala70, Met120, Tyr122, Glu127, Leu173,
Thr183 and Phe327 (Figure 5; Table 2). In addition,
staurosporine also forms van der Waals contacts with
Phe54, Lys72, Gly126 and Asp184. On the other hand, van
der Waals interactions with Val104, Thr51, and the P-3
Arg18 of PKI(5–24), seen with the adenosine moiety of
AMP-PNP, do not occur with staurosporine due to confor-
mational changes of the enzyme and the peptide. The
total number of contacts between staurosporine and the
enzyme (69 van der Waals, four polar) is much larger than
compared to the adenosine moiety (40 van der Waals,
eight polar; Table 2). staurosporine has a total surface
area of 411 Å2, 86 Å2 of which is accessible to solvent in
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Figure 3
Staurosporine at its binding site with the final
| 2Fo–Fc | density in blue contoured at 1.0s .
The | Fo–Fc | density contoured at 2.5s at the
stage of refinement before the staurosporine
was build in, is shown in green. Staurosporine
is shown in red and enzyme sidechains are in
gray.
Figure 2
Rotation of the N lobe. Superposition of
St–rCa –PKI (light purple Ca atom trace) with
AMP-PNP–mC–PKI (blue Ca atom trace) and
mC–PKI (green Ca atom trace). For alignment
the central helices E and F from the C lobe
were used. Every fiftieth Ca atom from
St–rCa –PKI is labeled; staurosporine is
shown in ball-and-stick representation.
the complex, leaving a buried surface area of 325 Å2.
Mn2+AMP-PNP in the ternary complex has a total surface
area of 377 Å2, 335 Å2 of which is buried, an area compara-
ble to the buried surface of staurosporine. While the Km of
MgATP in the kinase reaction is 10 m M, its KD in the pres-
ence of PKI(5–24) was found to be 7.3 nM using an acrylo-
dan modified catalytic subunit [37] or 23 nM measured
by surface plasmon resonance (for this measurement the
peptide was immobilized, and the binding kinetics of Ca
were determined under varying concentrations of ATP
with a BIAcore2000TM instrument; AL Picciolo and D
Bossemeyer, unpublished results). These values are com-
parable to the Ki of staurosporine for cAPK, which is
between 2 and 15 nM [5,17]. The nature of this binding
synergism has been attributed to a hydrogen-bonding
network involving ATP, the glycine flap, and the sub-
strate recognition sequence of PKI(5–24) [31], as well as to
peptide N-terminal signals [37].
Conformational changes in the vicinity of staurosporine
Staurosporine is much larger than adenosine, with more
limited flexibility (Figure 4). Staurosporine extends over
10.9 Å across the indole carbazole rings I to III; this is two
and a half times the size of a purine double ring with a
4.4 Å extension. The atoms which are involved in forming
hydrogen-bonds to the enzyme are also more widely sepa-
rated in staurosporine, as compared with adenosine. N31
of the methamino group and O30 (9.38 Å apart) or N19
(9.35 Å apart) are about 1 Å further apart than the corre-
sponding 3¢ OH and N6 or N1 of AMP-PNP (8.21 Å and
8.75 Å apart, respectively). From studies with lin-benzo-
adenine [38] and from the binding mode of isoquinoline-
sulfonamide inhibitors [19], it is known that the adenosine
pocket can accommodate more extended ring systems than
adenine. Changes in the N6 position, however, have detri-
mental effects, as in the case of 1,N6-etheneadenine or
guanine nucleotides. Bulky substitutions, as in some purine
analogs, can cause different ligand-binding modes [39]. In
agreement with this, staurosporine does not extend beyond
the N6 position of AMP-PNP (Figure 4).
Accommodation of the greater volume of staurosporine
leads to significant conformational changes of nearly all
the enzyme residues which are in contact with the
inhibitor (Figure 7a) compared to their positions in the
AMP-PNP–mC–PKI structure. An exception to this is
residue Phe54 of the glycine flap, which approaches the
inhibitor (see below). Relatively small movements occur
at Leu173, which stabilizes the plane of staurosporine
from the bottom, Glu127 and Glu170 (Table 3). Tyr122,
which shields the adenosine pocket from the region con-
necting the two lobes, moves 1.3 Å at its C d atom. Larger
displacements are seen for Thr183, the neighboring residue
of invariant Asp184 (which moves about 2.2 Å at the O g
atom) and for Met120 (a 2.0 Å movement at Ce ). The
sidechain of Met120 moves 0.8 Å in the presence of iso-
quinolinesulfonamide inhibitors [19]. The largest struc-
tural changes among the adenosine-binding pocket residues
are seen at Phe327 from the nonconserved C-terminal tail.
Figure 5
The staurosporine-binding site. Staurosporine
is shown in green stick form; enzyme residue
sidechains are in yellow. Hydrogen-bond
interactions are depicted as dotted lines;
water molecules are shown as blue balls.
Figure 4
Comparison of the kinase bound structures of staurosporine (thick
lines) and AMP-PNP (thin lines). The overlay was reached by
superimposing helices E and F of St–rCa –PKI with those of AMP-
PNP–mC–PKI. Atoms of staurosporine are labeled, the indole
carbazole six rings are numbered with Roman numerals. Atoms are
shown in standard colors.
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Its phenyl ring is not only translated by more than 3–4 Å,
but also rotated by almost 90° into an orientation compati-
ble with perpendicular aromatic–aromatic packing against
the indole carbazole ring I. The backbone of Phe327 is
shifted by 2.4 Å at the Ca atom.
The opening of the N lobe
The similar planarities of the staurosporine ring system and
adenosine require a similar spatial arrangement and indeed
none of the residues in contact with the inhibitor shows sig-
nificant displacement in an axial direction. Part of the N
lobe, however, undergoes a motion perpendicular to this
direction to form a unique open structure. St–rCa –PKI
differs from other known open structures in those structural
parts of the N lobe which directly contact the inhibitor via
sidechain interactions. These contacting residues, Leu49,
Val57 and Ala70, approach the inhibitor, providing many
van der Waals interactions (Table 2) and a perfect fit
(Figures 6a,b). To understand the forces which lead to the
opening of the other parts of the N lobe, we looked for
potential steric conflicts of the inhibitor with residues of the
N lobe. Direct and indirect steric conflicts can be recog-
nized. Firstly, the Val57 position in the ternary AMP-
PNP–mC–PKI complex would clash with the staurosporine
C35 methyl position (Figure 7b). The actual Val57 position
therefore is translated towards the lactam ring in order to
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Table 2
The number of van der Waals interactions of staurosporine
and the adenosine moiety with enzyme residues.
Staurosporine Adenosine moiety
Residue SCC MCC H-bond SCC MCC H-bond
Leu49 5 3 1
Gly50 – 3 4
Thr51 – – – 1
Phe54 1 –
Val57 13 – 11
Ala70 6 – 4
Lys72 1 – –
Val104 1
Met120 2 – 3
Glu121 – – 1 MCC 1 MCC
Tyr122 2 2 1
Val123 – 1 1 MCC 1 MCC
Gly126 – 2
Glu127 6 - 1 SCC 2 2 SCC
Glu170 1 4 1 MCC 1 MCC
Leu173 4 – 6
Thr183 4 – 4 1 SCC
Asp184 4 2
Phe327 3 – 2
PKI-Arg18 2 SCC
Total 52 17 4 35 5 8
SCC = sidechain contact; MCC = mainchain contact.
Figure 6
Fit of the staurosporine-binding pocket.
Comparison of the Connolly surface of
staurosporine (orange solid surface) with the
inner Connolly surface of the enzyme, when
staurosporine is omitted (net surface). (a) The
viewing axis is along the plane of
staurosporine, with the indole carbazole ring I
in front. (b) The view onto the plane of
staurosporine (bottom plane according to
orientation of Figure 1) with the C34 methoxy
group in the middle (view of (a) rotated 90°
around the x axis).
maintain contact with the staurosporine molecule, but also
to make room for the C35 group. Secondly, the greater
volume of staurosporine at the lactam ring and at the indole
carbazole ring III causes the backbone at residues Met120,
Glu121 and Val123, which are part of the hinge region
between both lobes at the end of strand b 5, to move away
and downwards (see orientation of Figure 1). Thirdly, an
indirect steric conflict with N lobe residues is caused by
Thr183. To maintain van der Waals distance to Thr183,
Val104 (which precedes strand b 4) has to move by 1.7 Å at
the Cb atom, and 1.3 Å at the Ca atom. Taken together, the
part of the N lobe which directly contacts staurosporine
undergoes a sliding movement parallel to the plane of
staurosporine towards the hinge region. Apparently, the
peptide connection to b 4 and the hinge region following b 5
are the levers that transform this translational movement
into a screw-like opening rotation of the remaining struc-
tural elements of the N lobe.
Conformational changes of the glycine flap
The flap-like glycine-rich sequence Gly50-Thr-Gly-Ser-
Phe-Gly-Arg-Val (where invariant residues are in bold) of
protein kinases is structurally unique among nucleotide-
binding proteins. The flap is involved in multiple func-
tions, such as nucleotide and substrate binding, catalysis,
and regulation of kinase activity [40]. This sequence con-
nects the first two strands b 1 and b 2. Because of its rela-
tive mobility in complexes with H-7 or H-8 it can occupy
upper and lower positions [19], and shows high B values in
binary complexes with PKI(5–24) [28]. In the ternary com-
plexes with nucleotide triphosphate and PKI(5–24), the
glycine flap is in a closed and fixed conformation [30,31],
in the complex of rC a with H-89 the element is fixed in
an open conformation. Phe54 is one of the two residues
on the tip of this flap. In the St–rCa –PKI structure
(Figure 8a), the glycine flap is in an open conformation
with distortions at the Phe54 position, this residue bends
inwards towards the inhibitor molecule. The sidechain of
Phe54 makes a van der Waals contact to the C35 methyl
group, shielding this part of the cleft. In contrast to the
isoquinolinesulfonamide inhibitor cocrystal structures, the
glycine flap occupies one single position only. The open
conformation of the glycine flap differs from its open
conformation in the binary complex with diiodinated
PKI(5–24) [34]. In the latter structure, the flap is shifted
away from the cleft as a whole, while in the St–rCa –PKI
complex residues Leu49 and Val57 have positions similar
to those in the AMP-PNP–mC–PKI structure, and the
opening of the flap is rather a rotation about an axis
through these two residues.
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Figure 7
Staurosporine induced conformational
changes. (a) Enzyme residues in the vicinity of
staurosporine. Residues rendered as stick
models are from the St–rCa –PKI complex,
residues from AMP-PNP–mC–PKI are
represented as lines. Staurosporine is shown
in yellow stick form; atoms are in standard
colors. (b) Direction of the concerted
movements of the N lobe elements.
St–rCa –PKI is shown in purple lines, AMP-
PNP–mC–PKI is shown in green lines. The
arrows indicate the direction of movements of
N lobe elements in the vicinity of
staurosporine upon inhibitor binding. The view
is from the back compared to Figure 1.
Conformational changes of the C-terminal tail
The nonconserved residues of the C terminus extend with
relatively few elements of higher secondary structure across
the surface of both lobes of the enzyme. One residue of the
C terminus Phe327, is part of the adenosine pocket and is
completely expelled from its position by the indole car-
bazole ring I (Figures 7a and 8b). The course of the C-ter-
minal tail of St–rCa –PKI, as shown in Figure 8b, follows
the course of the C-terminal tail of AMP-PNP–mC–PKI,
before the polypeptide chain passes the cleft. In the region
of the cleft it occupies an intermediate position between
that of the ternary and the open binary conformation, with
severe distortions caused by the voluminous inhibitor
molecule in the region around residue Phe327. The C-ter-
minal residues of the tail approach their position in the
open conformation of mC–PKI, apparently following the
rotation of the N lobe, to which they are anchored.
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Table 3
Conformational changes in the vicinity of staurosporine. 
Rmsd (Å)
Residue Mainchain All
Leu49 1.012 0.913
Gly50 1.818 1.886
Thr51 2.517 2.776
Phe54 3.232 6.125
Val57 1.426 1.228
Ala70 1.085 1.010
Lys72 1.601 1.773
Val104 0.860 1.350
Met120 1.052 1.355
Glu121 1.023 1.820
Tyr122 1.012 1.045
Val123 0.696 0.630
Gly126 0.818 0.729
Glu127 0.235 0.349
Glu170 0.375 0.384
Leu173 0.336 0.421
Thr183 1.831 2.411
Asp184 1.215 1.382
Phe327 2.307 2.891
PKI-Arg18 0.655 3.054
St–rCa –PKI and AMP-PNP–mC–PKI were superimposed at residues
140–159 and 219–232, which align with a root mean square deviation
(rmsd) of 0.225 Å. The rmsd of mainchain atoms and of all residue
atoms were determined using the program LSQMAN [53].
Figure 8
Staurosporine induced conformational changes. (a) The glycine flap
residues 49 to 57 of St–rCa –PKI (stick model) are shown in
comparison with the glycine flap of the ternary AMP-PNP–mC–PKI
structure (thin lines). Note the movement of Phe54 towards the C35
methyl group of staurosporine; the metal ions in the AMP-PNP–mC–PKI
structure are shown as blue stars. (b) Conformational differences
between the C-terminal tails of mC–PKI (open binary complex; green
Ca trace), St–rCa –PKI (pink Ca trace) and AMP-PNP–mC–PKI
(closed conformation; purple Ca trace). Note the structural changes of
the Phe327 positions. (c) Conformational changes of active-site
residues from the metal-binding loop and catalytic loop in comparison
to AMP-PNP–mC–PKI (thin lines). The St–rCa –PKI model is rendered
as a stick representation.
Conformational changes of the catalytic loop and the
metal-binding loop
In addition to the large scale conformational changes of the
N lobe and C-terminal tail, a number of more limited but
significant conformational changes take place in other parts
of the enzyme. These include changes occurring at the
active site, that is, in the catalytic loop and the metal
binding loop which contains the conserved Asp-Phe-Gly186
(DFG186) motif. The aspartate residue (Asp184) of the
motif is responsible for binding the activating Mg2+ ion,
and the invariant Phe185 is assumed to be a hydrophobic
anchor for Asp184. The metal-binding loop precedes the
activation segment, which carries the phosphorylated
residue Thr197. The primary cause of conformational
change in this region appears to be the displacement of
Thr183, which is transmitted via the peptide backbone
(Figures 7a and 8c). The catalytic loop carries a number of
the protein kinase invariant or highly conserved residues:
Asp166, the catalytic base; Lys168, a residue neutralizing
the charge at the g -phosphate of ATP; Glu170, a binding
partner for the pseudo-substrate peptide; and invariant
Asn171, ligand of the second bound metal ion in the AMP-
PNP–mC–PKI complex. All of these residues show some
movements; Asp166, the catalytic base, is especially notable
as it adopts a different sidechain orientation towards Asp184
(Figure 8c). In this position, the Asp166 carboxylate no
longer contacts the hydroxyl of Thr201, as in the AMP-
PNP–mC–PKI complex, but instead approaches the Asp184
carboxylate, presumably to share a hydrogen bond. While
the conformational changes of both the catalytic and metal-
binding loops seem to be unrelated to the domain rotation
of the N lobe, at least the movement of the metal-binding
loop appears to be caused by sterical conflicts upon stau-
rosporine binding.
Selectivity of staurosporine
Most kinases appear to be sensitive to staurosporine. One
exception, however, is mammalian protein kinase CK-1,
which is inhibited with a Ki of 163.5 m M [17]. We superim-
posed the recently solved crystal structure of rat CK-1
(PDB entry code 1CKJ [41]) onto St–rCa –PKI to help us
explain this weak interaction. The adenosine-binding
pocket of CK-1 differs in a number of residues from the
cAPK C subunit and from other kinases, in particular
at positions Val57 (Ile26 in CK-1 numbering), Thr183
(Ile153), Leu95 (Tyr59) and Glu127 (Ser91). The first
three of these substitutions introduce larger residues.
With regards to staurosporine binding, a certain amount of
flexibility appears to be required within the adenosine-
binding site in order to accommodate the inhibitor, as is
the case in the cAPK C subunit. In the more sterically hin-
dered CK-1 protein kinase, the flexibility would seem to
be insufficient to accommodate the staurosporine mol-
ecule. In addition, the replacement of Glu127 in cAPK by
Ser91 in CK-1 would presumably eliminate the hydrogen-
bond interaction of this residue with N31 of staurosporine.
Thus, comparing the two structures might provide esti-
mates of the energetic costs of kinase flexibility, relating
the conformational changes seen in St–rCa –PKI, and the-
oretically larger conformational changes in the adenosine-
binding pocket of CK-1 and correspondingly lower
binding energies.
Biological implications
Protein kinases play a key role in cellular signaling and
unregulated activities of protein kinases have been asso-
ciated with cancer and other diseases. The prototype
protein kinase inhibitor staurosporine, a microbial alka-
loid from Streptomyces sp., is the most potent general
inhibitor of protein kinases. Staurosporine has signifi-
cant cytotoxic and antiproliferative effects in vitro and
several of its related analogs show antitumor activity in
animal models and are candidates for clinical trials.
Staurosporine binds to the adenosine-binding pocket of
the catalytic subunit of the cAMP-dependent protein
kinase. In order to achieve tight binding, staurosporine
utilizes induced-fit structural changes, mimicks aspects
of the adenosine moiety and makes extensive use of the
conformational flexibility of enzyme residues and struc-
tural elements. The inhibitor binding results in an
almost perfect fit with many van der Waals interactions
and characteristic polar contacts, which explain the high
inhibitory potential of staurosporine for protein kinases.
At the same time, the structure defines a previously
unknown range of enzyme flexibility, the knowledge of
which is prerequisite for the evaluation and prediction of
specific inhibitor binding, and for the design of improved
protein kinase inhibitors.
Materials and methods
Protein expression and purification
Expression of recombinant bovine Ca catalytic subunit in Escherichia
coli, affinity purification of the enzyme and separation of differently
phosphorylated isoforms [42] was done essentially as described previ-
ously [19,43], except that the cells were broken using a French press
at 20.000 PSI.
Protein crystallization and data collection
The protein solution eluted from the Mono S column was exchanged
against 5 mM Mes-Bis-Tris pH 6.9, 75 mM LiCl, 0.1 mM EDTA, 1 mM
DTT and concentrated to 18 mg/ml using a Centricon 30 concentrator
(Amicon). The final concentration step was performed in the presence
of molar excess staurosporine (Boehringer Mannheim) and PKI(5–24).
The protein solution was made 25 mM in Mes-Bis-Tris pH 6.4, 1.5 mM
octanoyl-N-methylglucamide [36], and was equilibrated in hanging drops
at 5°C against 15% methanol. Crystals grew within five weeks. Several
crystals were harvested and indexed. Hanging drops containing crystals
were provided with additional 300 m M staurosporine, and incubation
continued. After a total of four months, crystals were harvested directly
from the droplets for cryocrystallography, using 35% glycerol as a cry-
oprotectant. Intensities data were collected from one crystal at 113K
using a Cryosystem (KGW, Karlsruhe), an imaging plate scanner (MAR-
research, Hamburg) and graphite monochromatized CuKa radiation from
a RU 200 rotating-anode generator (Rigaku, Tokyo, Japan) operating at
5.4 kW. The data were processed with the program packages MOSFLM
[44] and AGROVATA/ROTAVATA [45]. For statistics see Table 1. The
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prolonged incubation of crystals in the presence of extra staurosporine
had no significant effect on the unit cell parameters.
Structure solution
A model of the known structure [31] without any cofactors was taken for
Patterson search with the program AMoRe [46] giving a solution with a
correlation of 58.4 and an initial R factor of 37.6% for a resolution to
3.5 Å. The free R factor [47] was introduced before any refinement step
was done. After two cycles of refinement on position and B factors and
simulated annealing using the program X-PLOR [48] with Cambridge
Data Base derived parameters [49] (interrupted by manual model
rebuilding using the program O [50]) on a Silicon Graphics workstation
a clear density in the | Fo–Fc | map for the staurosporine appeared
(Figure 3). When the staurosporine structure [51] was built in, the
density showed an inverted configuration compared to the original struc-
ture which was then used for further refinement. This staurosporine con-
figuration corresponds to the X-ray structure of 4¢ -N-methylstaurosporine
methiodide [52]. Due to the high B factors the C-terminal sequence from
residue 316 to 340 was omitted from the refinement; the subsequent
| Fo–Fc | map, however, showed the mainchain of the entire protein.
Therefore this sequence was rebuilt and retained in the refinement
despite high B factors. Due to the high free R factor a real space correla-
tion analysis was performed. The residues 317–319 showed the lowest
real space correlations with 60%. Several residues with sidechains point-
ing toward the solvent, the first two residues at the N terminus and the
residues 31–33 showed correlations of 70–75%. All other residues
showed higher correlations mostly in the range of 82–92%. The unde-
fined N terminal residues 1–14, the two undefined C-terminal residues of
the PKI(5–22) peptide, and the apparent disorder at residues 317–319
probably account for the relatively high free R factor. Table 1 shows the
final statistics of the refinement. In the Ramachandran plot one residue in
the generously allowed region, while 88% of the residues are in the most
favored region.
Conformational changes
The relative opening of the N-terminal domains from St–rCa –PKI and
mC–PKI relative to the closed conformation of AMP-PNP–mC–PKI
have been determined by calculating the positional changes from the
C-terminal domain to the N-terminal domain alignments using the
program X-PLOR. Rmsd values for movements of residues have been
obtained using the program LSQMAN [53] after aligning residues
140–159 and 219–232.
Accession numbers
The atomic coordinates of St–rCa –PKI are available from the Brookhaven
Protein Data Bank with entry code 1STC. Alternatively they can be
obtained via e-mail from bossemeyer@dkfz-heidelberg.de.
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